A

Akebia Therapeutics
D

AKBA

1.87000
USD
0.06
(3.31%)
Market Closed
Volume
26,980
EPS
-0
Div Yield
-
P/E
-9
Market Cap
407,998,848
Related Instruments
    A
    AGEN
    -0.05000
    (-1.80%)
    2.72500 USD
    D
    DVAX
    -1.180
    (-8.81%)
    12.210 USD
    GILD
    GILD
    -3.715
    (-4.03%)
    88.385 USD
    GSK
    GSK
    -1.020
    (-2.97%)
    33.350 USD
    I
    INCY
    -1.840
    (-2.37%)
    75.890 USD
    K
    KPTI
    -0.02960
    (-3.54%)
    0.80740 USD
    K
    KURA
    -0.560
    (-3.40%)
    15.920 USD
    M
    MGNX
    -0.23000
    (-6.04%)
    3.58000 USD
    MRK
    MRK
    -2.050
    (-2.08%)
    99.16 USD
    More
News

Title: Akebia Therapeutics

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics for people with kidney disease. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor, is approved in Japan for the treatment of anemia due to chronic kidney disease,in adult patients, HIF-PH inhibitors in preclinical development.